Treatment of Sleepwalking (Somnambulism)
Clonazepam is the first-line medication treatment for sleepwalking, with a starting dose of 0.5-1.0 mg at bedtime. 1
Understanding Sleepwalking
Sleepwalking (somnambulism) is a non-REM sleep parasomnia characterized by complex behaviors during sleep, including walking. It affects approximately 2-14% of children and 1.6-2.4% of adults 1. While occasional episodes may be managed conservatively, recurrent sleepwalking with risk of injury requires pharmacological intervention.
Treatment Algorithm
First-line pharmacological treatment:
Alternative medications (if clonazepam is contraindicated or ineffective):
Treatment of underlying causes:
Safety Considerations
Environmental safety measures are crucial:
- Remove potentially dangerous objects from the bedroom
- Pad hard and sharp surfaces around the bed
- Cover windows with heavy draperies
- Consider placing the mattress on the floor to prevent falls 2
Special considerations for elderly patients:
Monitoring and Follow-up
- Beneficial effects of clonazepam are typically observed within the first week of treatment 2
- Discontinuation of treatment usually results in recurrence of symptoms 2
- Long-term treatment may be necessary, as studies have shown sustained efficacy with low risk of dosage tolerance 5
Important Caveats
- While clonazepam is the most established treatment for sleepwalking, there is a lack of high-quality randomized controlled trials specifically for somnambulism 6
- Paradoxically, some hypnotic medications like zolpidem may actually induce sleepwalking in some individuals 7
- Clonazepam should be used with caution in patients with concomitant obstructive sleep apnea 2
- Long-term benzodiazepine treatment for parasomnias has shown sustained efficacy with low risk of tolerance or abuse when properly prescribed and monitored 5
By addressing both the symptom (sleepwalking) and any underlying sleep disorders, this approach provides the most comprehensive management strategy for patients with somnambulism.